Eli Lilly, Zyprexa, and the Bush Family
“The most important story about Eli Lilly is that Lilly’s two current blockbuster psychiatric drugs—Zyprexa and Prozac—are, in scientific terms, of little value. It is also about how Lilly and the rest of Big Pharma have corrupted psychiatry, resulting in the increasing medicalization of unhappiness. This diseasing of our malaise has diverted us from examining the social sources for our unhappiness—and implementing societal solutions.”
Eli Lilly, Zyprexa, & the Bush Family
Bruce E. Levine, PhD, is a psychologist and author of Commonsense Rebellion: Taking Back Your Life from Drugs, Shrinks, Corporations and a World Gone Crazy (New York-London: Continuum, 2003).
“Whistleblower charges medical oversight bureau with corruption”
British Medical Journal July 10, 2004
Allen Jones, who worked as an investigator in the Pennsylvania Office of the Inspector General (OIG), gained widespread attention as a ‘whistleblower’ after voicing concerns about attempts by the pharmaceutical industry to implement a mental health screening plan, based on the controversial Texas Medication Algorithm Project (TMAP), in Pennsylvania.
Jones was escorted out of his workplace on April 28, 2004, after OIG officials accused him of talking to the press. Jones was relieved of his duties because he breached OIG guidelines that no worker may report confidential data. Jones indicates he chose to disclose his findings to the press precisely because of corrupt behavior by OIG officials themselves, alleging the OIG’s policy was “unconstitutional.”
Jones further alleged, in a wrongful termination suit, OIG officials had sought to “coverup, discourage, and limit any investigations or oversight into the corrupt practices of large drug companies and corrupt public officials who have acted with them.” http://en.wikipedia.org/wiki/Allen_Jones_(whistleblower)
Allen Jones’ TMAP Critique (January 20, 2004) on the net at http://psychrights.org/Drugs/AllenJonesTMAPJanuary20.pdf
Study Finds a Link of Drug Makers to Psychiatrists
New York Times
April 20, 2006
“More than half the psychiatrists who took part in developing a widely used diagnostic manual for mental disorders had financial ties to drug companies before or after the manual was published, public health researchers reported yesterday.”
“In recent years, critics have said that the manual has become too expansive, including diagnoses, like social phobia, that they say appear tailor-made to create a market for antidepressants or other drugs.”
See also “Medicating Aliah” http://www.motherjones.com/